]>
IRCT20180825040860N1 IRCT 2019-09-28 Esfahan University of Medical Sciences The efficacy of Eplerenon drug in patient with Acute CSCR (Central SerousChorioretinopathy) The efficacy of Eplerenon drug in patient with Acute CSCR (Central SerousChorioretinopathy) 2019-09-23 anticipated 40 Complete https://irct.ir/trial/33527 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: we divided patients randomly (with Dr.Saghaei's software) into 2 groups; 20 participants in "treatment group" and 20 participants in "placebo group", Blinding description: In the current study, neither patients nor physicians were not aware that every patient has been categorized in the treatment group or placebo group. The participating individuals were randomely categorized in treatment or placebo groups by using Dr. Saghaei software. after diagnosis, the patients were randomly divided into two groups (Placebo/treatment). the physician does not know the patients are in which group during visiting and follow-up. also none of the patients knows their classification until end of study. After the disease was diagnosed by specialist and resident of ophthalmology, participants were referred to secretory an he/she delivered placebo or drug to participants. In following up visits, results of tests were gathered by secretory and after doing anonymously, the results were delivered to an epidemiologist. after analysis, it was cleared that each data and analysis were related to each group. All of the patients were awarded regarding their classification (placebo or treatment group) after the study was done. 3 Central Serous Chorioretinopathy. Intervention 1: Intervention group: for patients of treatment group, Eplerenon was initiated. in the first week, 25 mg daily and for the three next weeks, 50 mg daily was administered. Intervention 2: Control group: for patients of control group, placebo was administered for 4 weeks. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No more information is available
public Mohammad Tohidi
Feiz Eye Hospital, Qods Sq, Isfahan
Isfahan Iran (Islamic Republic of) 8149644874 +98 31 3445 2031 dr.tohidi1387@yahoo.com Esfahan University of Medical Sciences scientific Alireza Dehghani
Feiz Eye Hospital, Qods Sq., Isfahan
ISfahan Iran (Islamic Republic of) 8149644874 +98 31 3445 2031 dehghani@med.mui.ac.ir Esfahan University of Medical Sciences Iran (Islamic Republic of) Acute onset of disease (less than 3 months) without history of previous treatments including treatment with drugs, PDT, Photocuagulation LASER absence of any pathology and impaired vision in other eye absence of ophthalmic eye pathology such as Glaucoma, Retinal disease and uveitis not taking corticostroids agents normal kidney lab tests for "treatment" group having consent to participating in study 18 years no limit Both does not having Consent to participating in study Younger than 18 years old suffering from any ocular or kidney disease H35.71 Central serous chorioretinopathy Treatment - Drugs Placebo Intervention group: for patients of treatment group, Eplerenon was initiated. in the first week, 25 mg daily and for the three next weeks, 50 mg daily was administered. Control group: for patients of control group, placebo was administered for 4 weeks. Best Corrected visual aquity. Timepoint: before and one month after initiation of intervention. Method of measurement: snellen chart. Central macular thickness. Timepoint: before and one month after initiation of intervention. Method of measurement: optical coherence topogrphy. Macular volume. Timepoint: before and one month after initiation of intervention. Method of measurement: optical coherence topogrphy. Choroidal thickness. Timepoint: before and one month after initiation of intervention. Method of measurement: optical coherence topogrphy. Adverse effects of eplerenon. Timepoint: during intervention. Method of measurement: questionnaire. Esfahan University of Medical Sciences Approved 2019-02-17 Ethical Committee of Isfahan University of Medical Sceinces Hezar Jareeb str., Azadi Sqr. Isfahan Isfehan Iran (Islamic Republic of)